StoneRidge PMG Advisors, LLC’s Esperion Therapeutics ESPR Stock Holding History
Bought
Maintained
Sold
Other funds holding ESPR
StoneRidge PMG Advisors, LLC's ESPR Position: Q3 2026 in Review
StoneRidge PMG Advisors, LLC sold out of Esperion Therapeutics (ESPR) in Q3 2026, closing a stake of 18,237 shares — an estimated $58K sold.
StoneRidge PMG Advisors, LLC first reported a position in ESPR in Q2 2023 and held it in 7 quarters. The position peaked at $262K in Q2 2024. 2 funds tracked by Wall St. Rank hold ESPR as of Q3 2026.
- StoneRidge PMG Advisors, LLC reported no remaining Esperion Therapeutics position as of Q3 2026 after selling out during the quarter.
- StoneRidge PMG Advisors, LLC sold 18,237 Esperion Therapeutics shares in Q3 2026, an estimated $58K.
- StoneRidge PMG Advisors, LLC first reported a position in Esperion Therapeutics in Q2 2023 and held it in 7 quarters.
- StoneRidge PMG Advisors, LLC's Esperion Therapeutics position peaked at $262K in Q2 2024.
- 2 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q3 2026.
Based on StoneRidge PMG Advisors, LLC's 13F filing for Q3 2026, filed 4 Nov 2026.